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Proteoliposomal formulations of 
an HIV-1 gp41-based miniprotein 
elicit a lipid-dependent 
immunodominant response 
overlapping the 2F5 binding motif
Luis M. Molinos-Albert1, Eneritz Bilbao2, Luis Agulló3, Silvia Marfil1, Elisabet García1, 
Maria Luisa Rodríguez de la Concepción1, Nuria Izquierdo-Useros1, Cristina Vilaplana4, 
Jon A. Nieto-Garai2, F.-Xabier Contreras2,5, Martin Floor3,6, Pere J. Cardona4,  
Javier Martinez-Picado1,7,8, Bonaventura Clotet1,8,9, Jordi Villà-Freixa3, Maier Lorizate2, 
Jorge Carrillo1,* & Julià Blanco1,8,*
The HIV-1 gp41 Membrane Proximal External Region (MPER) is recognized by broadly neutralizing 
antibodies and represents a promising vaccine target. However, MPER immunogenicity and antibody 
activity are influenced by membrane lipids. To evaluate lipid modulation of MPER immunogenicity, 
we generated a 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC)-based proteoliposome collection 
containing combinations of phosphatidylserine (PS), GM3 ganglioside, cholesterol (CHOL), 
sphingomyelin (SM) and the TLR4 agonist monophosphoryl lipid A (MPLA). A recombinant gp41-derived 
miniprotein (gp41-MinTT) exposing the MPER and a tetanus toxoid (TT) peptide that favors MHC-II 
presentation, was successfully incorporated into lipid mixtures (>85%). Immunization of mice with 
soluble gp41-MinTT exclusively induced responses against the TT peptide, while POPC proteoliposomes 
generated potent anti-gp41 IgG responses using lower protein doses. The combined addition of 
PS and GM3 or CHOL/SM to POPC liposomes greatly increased gp41 immunogenicity, which was 
further enhanced by the addition of MPLA. Responses generated by all proteoliposomes targeted the 
N-terminal moiety of MPER overlapping the 2F5 neutralizing epitope. Our data show that lipids impact 
both, the epitope targeted and the magnitude of the response to membrane-dependent antigens, 
helping to improve MPER-based lipid carriers. Moreover, the identification of immunodominant 
epitopes allows for the redesign of immunogens targeting MPER neutralizing determinants.
The HIV-1 envelope glycoprotein (Env) is a trimer of heterodimers composed by the non-covalent association of 
gp120 and gp41 subunits1. It is the sole viral protein exposed on the viral surface and, thus, is the main target of 
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neutralizing antibodies. In spite of more than 30 years of research, an immunogen capable of inducing a broadly 
neutralizing antibody response against Env has not been achieved yet. Due to the high viral variation rate and 
immune evasion, a successful preventive vaccine should target conserved functional epitopes within the envelope. 
The identification of a small percentage of broadly neutralizing humoral responses in different cohorts of HIV-1 
infected individuals highlighted the uncommonness but also the feasibility to develop this kind of responses 
by the human immune system2–6. Furthermore, the isolation of broadly neutralizing antibodies (bNAbs) from 
these individuals identified several antigenic vulnerability sites within Env including the CD4 binding site4,7–10; 
glycan-dependent epitopes defined by residues N160 and N332 in the V1/V2 and V3 gp120 loops respec-
tively10–12; the gp41 Membrane Proximal External Region (MPER)13–16; and recently discovered regions including 
residues from both gp120 and gp4117–19 and the gp41 fusion peptide20. The study of these regions has guided 
efforts in HIV-1 vaccine development during the last years21,22.
The MPER is a highly conserved tryptophan-rich region that has crucial roles in both viral fusion23,24 and 
CD4-independent transcytosis across the epithelial cell barriers25. Moreover, the MPER includes linear, tran-
siently exposed epitopes targeted by bNAbs such as 2F5, 4E10 and 10E8. All of them show a wide in vitro activity 
and are able to protect animals upon viral challenge in vivo16,26–28. Particularly 10E8 is one of the broadest and 
most potent bNAbs isolated to date16. Therefore, the MPER is considered as a potential HIV-1 vaccine target. 
However, several barriers to generate a neutralizing response against this region make MPER vaccine design 
considerably challenging14. Structurally, MPER peptide conformation is highly influenced by lipids and seems 
to be embedded into the viral membrane29,30, which is unusually rich in cholesterol (CHOL) and sphingomyelin 
(SM)31. Accordingly, anti-MPER bNAbs show cross-reactivity against lipids that seem to be essential for their 
neutralizing capacity32–35.
In order to dissect how lipids may modulate the immunogenicity of the MPER region, we generated a col-
lection of proteoliposomes containing a gp41-derived miniprotein, previously shown to overexpose the MPER 
region36. To overcome potential limitation in MHC-II presentation after antigen processing in C57 BL/6 mice 
and to increase immunogenicity, the original gp41-Min protein was engrafted in the C-terminal moiety with a 
tetanus toxoid (TT) promiscuous T-helper epitope37,38. Furthermore, liposomes included several structural lipids 
overrepresented in the viral membrane (CHOL and SM)31 and lipids that may influence immune responses by 
promoting selective capture by antigen presenting cells (APC). In this regard, we tested phosphatidylserine (PS) 
that binds to different receptors on the surface of phagocytic cells39,40, and the ganglioside GM3, which binds to 
CD169 (SIGLEC-1) on the membrane of subcapsular sinus macrophages41,42, a highly specialized antigen present-
ing cell population that play a pivotal role during the induction of the humoral response43. Moreover, monophos-
phoryl lipid A (MPLA), a ligand of TLR4, was included as molecular adjuvant44.
By using this proteoliposome collection, we systematically evaluated the individual contribution of lipid com-
ponents over MPER immunogenicity in mice, obtaining more than 2-log difference in serum antibody titers. We 
also mapped the responses elicited within the sequence of our immunogen. Remarkably, we found that proteoli-
posome presentation shifted the response from the TT peptide to the gp41 moiety of the immunogen. Moreover, 
regardless of the lipid composition used, the response targeted an epitope overlapping the 2F5-binding motif, 
revealing the existence of a gp41 immunodominant region that cannot be bypassed by any lipid mixture.
Results
Antigen design, production and characterization. From a recently described collection of gp41-
based miniproteins36, we selected a minimal gp41-based construction that greatly increased the MPER exposure, 
designed as gp41-Min. This protein contains the C-terminal heptad repeat (HR2), the MPER and the trans-
membrane (TM) domains of gp41. In order to overcome potential limitations in MHC-II presentation of the 
processed antigen37, a TT promiscuous T-helper epitope 830QYIKANSKFIGITEL84438 was fused in frame with the 
TM domain. A six-histidine tag was added at the C-terminal end to allow protein purification. This construct, 
designed as gp41-MinTT (Fig. 1a), was produced in E. coli. After metal affinity, gel filtration chromatography 
yielded a highly pure 15 kDa gp41-MinTT recombinant protein peak (Fig. 1b). The integrity of the protein was 
confirmed by SDS-PAGE/coomassie staining, Western blot and ELISA using the specific antibodies D50 (HR2) 
and 2F5 (MPER) (Fig. 1c,d).
Proteoliposome production and characterization. Since membrane environment influences the con-
formation of the MPER29, we generated gp41-MinTT-based proteoliposomes using POPC and lipids overrep-
resented in the viral membrane-like environment, such as CHOL or SM31,45,46. The molar ratios chosen mimic 
viral membrane composition and rigidity46. The proteoliposomes used in this study were classified as complex 
or simple according to the presence or absence of CHOL and SM, respectively. In addition, we included lipids 
that bind to several receptors on the surface of antigen presenting cells (APC), such as the GM3 ganglioside41 and 
PS47, to seek whether the route of presentation may influence the immunogenicity of gp41-MinTT. We selected 
a GM3 molar ratio that induces optimal capture by dendritic cells42. The same amount of PS was used. Finally, 
we evaluated the effect of the TLR4 agonist MPLA over the effect of complex proteoliposomes. A summary of 
the composition of the proteoliposomes used in this study is specified in Table 1. Proteoliposomes were labeled 
with rhodamine, which was incorporated as DHPE-Rho into lipid mixtures. Proteoliposomes were purified by 
ultracentrifugation on a sucrose gradient. Since proteoliposomes have a lower density than the protein alone, 
they float up and are recovered from the first two fractions (Fig. 2a). Protein signal was detected by silver staining 
that also allowed visualization of fluorescent lipids (Fig. 2a). Fluorescence signal was measured by plate reader to 
quantify lipid content, while protein content was assessed by quantitative Western blot in a LiCoR system, which 
allows measuring the signal of each sample in the linear range. All proteoliposomes incorporated more than 
85% of gp41-MinTT protein and showed an overall size distribution between 100–200 nm (Fig. 2b). The lipid 
amount ranged between 220–240 μ M with a protein/lipid molar ratio always close to 1:250 (Fig. 2b). The effect 
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of lyophilization and reconstitution on the protein content and size of proteoliposomes was routinely assessed by 
western blot and dynamic light scattering (DLS) respectively demonstrating no major differences before and after 
reconstitution (Supplemental Fig. 1). Consequently, all the proteoliposomes prepared were similar in size and 
lipid to protein mole ratio and, therefore, suitable for comparable immunization.
Interestingly, in the absence of lipids, gp41-MinTT protein showed a single monomeric band whereas in the 
presence of lipids, SDS and β -mercaptoethanol-resistant oligomeric bands appeared (Fig. 2b). Further charac-
terization of the secondary structure of gp41-MinTT in solution and embedded in lipid mixtures (simple or 
complex + MPLA) was performed by circular dichroism (CD). Gp41-MinTT protein in solution showed predom-
inantly an alpha-helix secondary structure with a positive absorption below 200 nm (data not shown) and two 
negative bands at 208 and 222 nm. Due to the complexity of proteoliposome samples, the spectra were recorded 
from 200 nm, since below this wavelength signal to noise ratio was too low. In the presence of lipids, the positive 
peak shifted to the red, and negative bands showed general loss of signal (Fig. 2c). This effect was more pro-
nounced for the 208 nm band in simple proteoliposome preparations. The shift of the positive band, together with 
the Ѳ222/Ѳ208 ellipticity ratio > 1, would support the existence of helix-helix interactions such as those described 
for heterodimeric coiled-coils48–51 and/or transmembrane helical bundles52. Seemingly, the protein in solution 
shows a Ѳ222/Ѳ208 ellipticity ratio < 1, which would be consistent with the disruption of helix-helix interactions or 
monomeric alpha-helix50. Finally, we evaluated the antigenicity of MPER in ELISA assays comparing the binding 
Figure 1. Gp41-MinTT expression and purification. (a) Schematic representation of gp41, gp41-Min and 
gp41-MinTT proteins is shown. FP, fusion peptide (blue); HR1, N-terminal heptad repeat (red); S-S, disulfide 
loop (brown); HR2, C-terminal heptad repeat (green); MPER, membrane proximal external region (yellow); 
TM, transmembrane domain (purple); CT, cytoplasmic tail (gray); TT, tetanus toxoid epitope (light green); 
6xHis, 6-histidine tag (orange). MPER-spanning sequence (residues 659–683, HXB2 numbering) is depicted. 
MPER sequences containing the 2F5, 4E10 and 10E8 epitopes are underlined. 2F5 neutralizing core and 
residues equally recognized by 4E10 and 10E8 are highlighted in blue and red respectively. (b) Gel filtration 
chromatography. Elution profile of the latter purification step is shown. (c) A highly pure 15KDa protein was 
recovered and concentrated from central fractions of the largest peak shown in panel B (44–49 mL fractions), 
as confirmed by SDS-PAGE and coomassie staining (left) and by Western blot using the 2F5 antibody (right). 
Molecular markers are indicated. (d) Antigenicity of purified gp41-MinTT protein determined by ELISA using 
serial dilutions of D50 (anti-HR2) and 2F5 (anti-MPER) antibodies.
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of 2F5 and 4E10 antibodies to gp41-MinTT presented as a recombinant protein or exposed on complex proteoli-
posomes (Fig. 2d). The results showed that 4E10 equally recognized both preparations. In contrast, 2F5 showed 
a reduced binding to proteoliposomes, suggesting that the 2F5 epitope was differently exposed in both contexts. 
To further assess the orientation of the immunogen on proteoliposomes, the exposure of the C-terminal end of 
gp41-MinTT protein was measured by ELISA. The results showed that the C-terminal end was poorly exposed 
on the outer surface of proteoliposomes (Supplemental Fig. 2). Therefore, these data indicated that most of the 
immunogen was properly exposed. The gp41 moiety was displayed on the surface whereas the C-terminal end 
was oriented towards the lumen of proteoliposomes.
Gp41-MinTT immunogenicity can be enhanced by modifying the lipid composition. C57 BL/6 
mice were immunized four times with 20 μ g of proteoliposomes (containing 2 μ g of gp41-MinTT protein) or with 
20 μ g of soluble recombinant protein in a 12-weeks immunization regimen. Three weeks after the last inoculum, 
anti-gp41 IgG titers were determined by ELISA using the gp41-Min protein, lacking the TT epitope36. Despite 
the lower inoculum dose used, all proteoliposome-immunized animals showed higher titers than those immu-
nized with soluble protein (Fig. 3a). A global comparison between animals immunized with simple and complex 
proteoliposome formulations showed at least 1-log anti-gp41 titer increase in the complex group, indicating the 
enhancing effect of CHOL/SM addition (Fig. 3a). When we evaluated the adjuvant activity of MPLA, we found 
an additional 1-log titer increase, highlighting the potential benefits of this TLR agonist on anti-gp41 responses 
(Fig. 3a). Moreover, the combined analysis of antibody titers against recombinant gp41-MinTT and the original 
gp41-Min proteins showed that mice immunized with recombinant gp41-MinTT presented gp41-MinTT binding 
in the absence of gp41-Min titers, indicating that the response was exclusively focused against the immunogenic 
TT epitope (Fig. 3b). In contrast, a strongly correlated response against both proteins (r = 0.8373, p < 0.0001) was 
found for proteoliposomal preparations, indicating that the humoral response generated by those formulations 
was mostly directed against the gp41 domain. These findings demonstrate that the humoral response induced by 
gp41-MinTT immunogen can be dramatically modulated by the addition of lipids, which not only increase the 
magnitude of antibody titers but also guide the response towards the gp41 domain.
We next evaluated the effect of individual lipid components over gp41-MinTT immunogenicity (Fig. 3c,d). 
Although a slight but not significant effect was observed in terms of immunogenicity when GM3 or PS were 
individually incorporated into simple compositions (Fig. 3c), we detected faster kinetics of anti-gp41 antibodies 
in GM3-containing liposomes (Fig. 3d). In spite of this, the individual contribution of GM3 or PS to the global 
response was not statistically significant in any of the conditions tested (Supplemental Fig. 3). However, a great 
increase in antibody titer was detected when both components were formulated together in the context of sim-
ple POPC formulations (Fig. 3c). This synergistic effect was not additive to the enhanced effect caused by either 
CHOL-SM or MPLA, since it was lost in complex formulations (Fig. 3c). Remarkably, we observed that kinetics of 
the antibody response were faster in those animals immunized with complex proteoliposomes as well as for those 
receiving GM3 and PS in combination (Fig. 3d).
Immunodominant response is focused on the N-terminal MPER region. In order to explore the 
gp41 regions targeted in immunized animals, we assayed sera against a collection of 15-mer overlapping pep-
tides covering the HR2 and the MPER of gp41 (Fig. 4a). The results, summarized in Fig. 4b, showed that the 
global response was mostly directed against a peptide, designed as #162 (residues 653–667), that overlaps between 
HR2 and MPER and includes the 2F5 binding domain (Fig. 4c). This major response correlated with the global 
anti-gp41-Min titer (Fig. 4d), indicating that humoral responses against this region are especially favored by 
FORMULATION LIPID COMPOSITION (molar ratio) PROTEIN DOSE/INOCULUM
Recombinant protein gp41-MinTT 20 μ g
Simple proteoliposomes
POPC (100) gp41-MinTT 2 μ g
POPC:GM3 (95:5) gp41-MinTT 2 μ g
POPC:PS (95:5) gp41-MinTT 2 μ g
POPC:GM3:PS (90:5:5) gp41-MinTT 2 μ g
Complex proteoliposomes
POPC:SM:CHOL (30:25:45) gp41-MinTT 2 μ g
POPC:SM:CHOL:GM3 (30:20:45:5) gp41-MinTT 2 μ g
POPC:SM:CHOL:PS (25:25:45:5) gp41-MinTT n.d.*
POPC:SM:CHOL:GM3:PS (25:20:45:5:5) gp41-MinTT 2 μ g
Complex proteoliposomes + MPLA
POPC:SM:CHOL:MPLA (29:25:45:1) gp41-MinTT 2 μ g
POPC:SM:CHOL:GM3:MPLA (29:20:45:5:1) gp41-MinTT 2 μ g
POPC:SM:CHOL:PS:MPLA (24:25:45:5:1) gp41-MinTT 2 μ g
POPC:SM:CHOL:GM3:PS:MPLA (24:20:45:5:5:1) gp41-MinTT 2 μ g
Table 1.  Gp41-MinTT-containing immunogens used in this study. Immunogens were categorized in 
recombinant protein (gp41-MinTT), simple (POPC), complex (POPC CHOL SM) and complex + MPLA 
(POPC CHOL SM MPLA) proteoliposomes. GM3, PS or both were added to each category. Percentages are 
referred to lipid components. Lipid mole ratios were used. POPC: 1-Palmitoyl-2-oleoylphosphatidylcholine; 
CHOL, cholesterol; SM, sphingomyelin; GM3, monosialodihexosylganglioside; PS, phosphatidylserine; MPLA, 
monophosphoryl lipid A. *n.d.: not determined.
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gp41-MinTT immunogen formulated within a membrane environment. Furthermore, complex formulations or 
addition of MPLA did not modify the specificity of the response that remained focused almost exclusively on the 
#162-covering region (Fig. 4b). We found hence that immunization with gp41-MinTT-based proteoliposomes 
Figure 2. Proteoliposomes characterization. (a) Silver stained gels (top) and Western blots (bottom) of each 
sucrose gradient fractions corresponding to representative proteoliposomes of different composition (simple, 
complex and complex + MPLA). After proteoliposomes floatation, a sample of each recovered fraction was 
used for silver staining and Western blot analysis. Proteoliposomes could be detected in the first two fractions 
(arrows) by the signals of the protein and lipids (asterisks). M: Molecular Weight Marker and numbering 1 to 6 
corresponds to the collected fractions from the top to the bottom of the ultracentrifuge tube. (b) Mean values 
and standard deviations of vesicle size, quantified protein and lipid amounts of each proteoliposome group are 
indicated. Ranges of protein/lipid ratios are also shown. Western blot analysis of the selected proteoliposome 
fractions for immunization is shown below. Purified gp41-MinTT protein was used as reference (left lane). 
(c) Secondary structure determination by circular dichroism. Near UV Spectra of gp41-MinTT in solution 
(black), simple (red) and complex + MPLA (green) proteoliposome formulations. Data are representative of 
two independent preparations. (d) Comparison of the antigenicity of gp41-MinTT-containing proteoliposomes 
(PTL, solid lines) and gp41-MinTT recombinant protein (RP, dotted lines) by ELISA using 2F5 (red) and 4E10 
(blue) antibodies. Graph shows specific signal (OD 492 nm) of serial dilutions of monoclonal antibodies against 
both antigens captured by D50 antibody. Samples were assayed in duplicate and values are expressed as the 
mean and the interquartile range. Data are representative of two independent experiments.
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generated an immunodominant response overlapping the N-terminal part of the MPER region, which contains 
the 2F5 binding domain.
To gain insights into the features of elicited antibodies, we analyzed the relevant residues for #162 binding. 
We selected 29 serum samples displaying the highest #162 binding signals, and we assayed those sera against a 
collection of peptides in which each position of the #162 sequence was substituted by an alanine residue (Fig. 5a). 
On average, we found that 6 residues (N656, E657, L660, L661, K665 and W666) were especially relevant for 
#162 binding (Fig. 5b). Importantly, four out of six of these residues are located within the MPER region and two 
of them (K665 and W666) correspond to the 2F5 neutralizing core (664DKW666)53. In contrast, only a reduced 
number of sera recognized the D664 residue within the 2F5 epitope. Furthermore, modest neutralization activity 
was observed against NL4–3 and BaL subtype B viruses (Supplemental Fig. 4), which correlated with binding to 
#165 and MPER peptides but not with reactivity against the #162 peptide (Supplemental Fig. 5). In addition, no 
differences in the binding pattern to #162 peptide residues between neutralizing and non-neutralizing sera were 
observed (data not shown). Therefore, the lack of reactivity against the C-terminal moiety of the MPER may have 
precluded the elicitation of more potent neutralizing responses.
Modeling of the immunodominant epitope in proteoliposomes. The lack of reactivity against the 
D664 residue and the immunodominance of peptide #162 were intriguing. In order to understand this reactiv-
ity, we generated an in silico model of the extracellular and TM sequences of gp41-Min protein embedded in a 
POPC or in a complex lipid bilayer. Molecular dynamics in POPC showed that the 6 relevant residues for #162 
binding belong to two different turns (turn A, segment 659ELLE662; turn B, segment 663LDKW666) of the MPER 
helix that are located on the membrane interface (Fig. 6a,b). The turn B, strongly interacts with the lipid bilayer 
throughout the dynamics (W666 with the hydrophobic environment of the bilayer and K665 with phospholipid 
polar heads; total non-bond interaction energy of − 55.2 kcal/mol), similar to the following two turns (turn C, 
residues A667 to W670: − 38.6 kcal/mol; turn D, residues N671 to D674: − 38.2 kcal/mol). On the contrary, the 
turn A containing N656, E657, L660 and L661, shows a much weaker interaction with the viral membrane (+ 
5.4 kcal/mol). Similar results were found for the gp41-Min model embedded in a complex bilayer (turn A: + 
12.6 kcal/mol; turn B: − 85.7 kcal/mol; turn C: − 130.0 kcal/mol and turn D: − 44.7 kcal/mol, Fig. 6c). Considering 
Figure 3. Effect of lipid composition on anti-gp41 IgG response. (a) Summary of anti-gp41-Min specific 
IgG titers, at sacrifice day, of C57 BL/6 mice immunized with gp41-MinTT proteoliposomes of simple (blue), 
complex (green) and complex incorporating MPLA (red) compositions. Data from animals immunized with 
control liposomes (black) and soluble gp41-MinTT protein (grey) are included. (b) Correlation of IgG titers, at 
sacrifice, against gp41-MinTT and gp41-Min antigens of mice immunized with gp41-MinTT as recombinant 
protein or formulated in proteoliposomes. (c) Influence of lipid mixtures over gp41-MinTT immunogenicity. 
Gp41-IgG titer at sacrifice day is shown. (d) Evolution of the gp41-Min IgG response of animals immunized 
with gp41-MinTT proteoliposomes based on POPC (upper left); POPC and GM3 (upper right); POPC and 
PS (down left); POPC combined with GM3 and PS (down right) in a simple, complex or complex with MPLA 
composition (blue, green and red lines respectively). Asterisks indicate immunization time points. In all panels, 
IgG titer is displayed as ng/mL referred to the D50 antibody, which was used as standard. Data show the median 
and interquartile range of at least two independent determinations. In panels (a) and (c), ***, ** and * denote 
p < 0.0001, p < 0.001 and p < 0.01 respectively. ns, not significant.
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the immunodominance of W666 and K665 residues and the proximity of the polar D664 (Fig. 6a,c), we explored 
whether hydration patterns could help to identify hot spots for strong protein-protein interactions. Polar resi-
dues, as K665 and D664, are extremely solvatable in water solution, making weaker interactions with other polar 
solvents than when they are in a water excluded patch54. We compared the water shell around D664, K665 and 
Figure 4. Mapping of humoral response against gp41-overlapping peptides. (a) 15-mer overlapping 
peptide collection covering the HR2 (OLP peptides #155–161) and the MPER (OLP peptides #162–166) used 
for mapping. (b) OD values of the indicated immunized mice sera (60-fold dilution) against OLP peptides 
in ELISA. 2F5 binding is also indicated. Color code is shown. (c) For each animal the peptide yielding the 
strongest signal was assigned 100%. Bar diagram shows the percentage of signal of each peptide in all animals 
(mean+ /− SD), highlighting the immunodominance of the #162 peptide sequence. (d) Spearman’s correlation 
of #162 binding signals and gp41-Min titer of immunized mice sera. Data are representative of two independent 
experiments. Spearman’s correlation coefficient and p value are indicated.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:40800 | DOI: 10.1038/srep40800
W666 for the membrane embedded protein models and the water-only solvated model. We observed that W666 
and K665 showed a lower level of hydration in both lipid bilayers when compared to soluble forms (Fig. 6d,e), 
while hydration of D664 was identical in both models, suggesting that extraction of W666 from the membrane 
will modify the hydration shell for K665 in a much larger extent than D664. In addition, the proximity of W666 
prevents water molecules to fully solvate the lysine residue, thus, offering a much favorable propensity to create 
strong charge-charge interactions with other proteins. Overall, this behavior may explain the observed selectivity 
of antibody binding to K665 and the similar immunodominance observed for the different lipid compositions.
Discussion
Anti-MPER bNAbs share a common neutralization mechanism in which interactions of CDRH3 hydrophobic 
residues with membrane lipids seem to be essential32,55–59. Additionally, MPER structure is influenced by mem-
brane lipid composition29,30. Therefore, it is widely assumed that the generation of a robust anti-MPER response 
should require its presentation within a membrane environment to properly present neutralizing determinants 
and to implement lipid cross-reactivity55,59–62.
In this study, we evaluated to what extend lipids may modulate the MPER immunogenicity. Accordingly, we 
selected an immunogen containing the HR2, the MPER and the TM domain of gp41 resulting in an increased 
MPER exposure compared with the whole gp41 protein36. Additionally, we incorporated a promiscuous T-cell TT 
epitope to harness the MHC-II antigen presentation pathway that has been shown as a major limiting factor in 
MPER responses in murine models37. Likewise, in a cohort of untreated HIV-1 infected viremic controllers it has 
been recently shown an association between gp41-specific CD4 T cell responses with the magnitude and breadth 
of anti-Env neutralizing antibodies63. We incorporated gp41-MinTT protein into liposomes of diverse composi-
tion. Starting from POPC-based liposomes, we increased the complexity by adding (i) CHOL/SM, to mimic the 
viral membrane31; (ii) GM3 and PS, to modulate delivery to specialized APCs (such as the CD169+ subcapsular 
sinus macrophages)43,47,64–66 and (iii) the monophosphoryl Lipid A, a TLR4 agonist approved for human use, as a 
molecular adjuvant44.
Our data show that animals immunized with the recombinant protein gp41-MinTT developed a weaker 
humoral response than those immunized with 10-fold lower inoculum dose of the same protein formulated 
as proteoliposomes. Interestingly, humoral response elicited by soluble protein was focused on the TT peptide, 
while proteoliposomes guided the humoral response towards the gp41 extra-cellular portion of the recombi-
nant protein, albeit the TT epitope was also exposed (data not shown). Secondary structure determination of 
the protein embedded in liposomes suggests a mostly alpha-helix structure, with some level of protein-protein 
interaction, absent in the soluble form. This is consistent with the oligomeric forms detected by SDS-PAGE anal-
ysis. Nevertheless, CD data only provides information on the overall secondary structure of the protein, with-
out specific epitope structure. Therefore, differences in oligomerization status in soluble and proteoliposomal 
Figure 5. Alanine-scanning analysis of the immunodominance against #OLP-162. (a) 29 mice sera 
displaying the highest signals against OLP#162 peptide were tested for binding against a collection of  
OLP#162-alanine mutants. Values indicate the binding percentage relative to the wild type peptide signal. 2F5 
profile is also included. Color code is indicated. (b) Percentage of residual binding (mean+ /− SD) for each 
alanine mutant peptide is shown. Immunodominant residues (< 50% residual binding) are highlighted in red in 
both panels. HXB2 numbering of Q653 and W666 residues is indicated in grey.
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Figure 6. In silico structural model of gp41-Min. (a) Structural model embedded in a POPC bilayer.  
(b,c) Detail of the helix turns containing relevant residues for #162 binding in POPC (b) and complex  
(c) bilayers. Gp41-Min protein is shown in a ribbon representation. The helix turn containing L660 and L661 
is shown in black and the turn containing W666 is shown in grey. In addition, all tryptophans present in 
gp41-Min and some residues specifically named in the text are labeled with arrows and represented as sticks. 
Lipid bilayers are represented as solvent accessible surface, truncated along the main protein axis to allow its 
visualization. (d,e) Number of water molecules within a sphere of 3 Å around lateral chains of residues D664 
(left), K665 (middle) and W666 (right) in the gp41-Min model embedded in a POPC (d) and complex  
(e) bilayers throughout the molecular dynamics. Mean values are represented by a continuous horizontal line. 
The respective mean values obtained from the molecular dynamics performed in the absence of the lipid bilayer 
(water-only solvated model) are also shown for comparison (discontinuous line).
www.nature.com/scientificreports/
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preparations, and changes in MPER exposure induced by lipids mimicking a native conformation, are probably 
reasons for enhanced immunogenicity of the gp41 moiety. Furthermore, we observed modest contributions of 
individual GM3 and PS incorporation into POPC proteoliposomes, although synergistic activity was noticed in 
this context, probably due to multivalent presentation of both ligands through different pathways. In contrast, 
incorporation of CHOL and SM significantly increased the gp41-MinTT immunogenicity compared to the sim-
plest POPC proteoliposomes. This immunogenicity boost supports the notion that certain lipids may modulate 
the MPER structure and/or accessibility by modifying its membrane insertion index29,67 or membrane fluidity, 
accounting for a higher antibody response68,69. The membrane of HIV-1 virions shows an unusual high content of 
sphingolipids and CHOL31, which seems to be essential for MPER-induced membrane fusion70,71. Furthermore, 
the C-terminal end of the MPER contains the LWYIK “Cholesterol Recognition Amino acid Consensus” (CRAC) 
motif by which MPER-CHOL interactions would be supported72. Despite this, molecular dynamics showed simi-
lar exposure of the immunodominant domain on the surface of simple and complex membrane. Consistently, no 
changes in targeted epitopes were observed among simple or complex proteoliposomes; thus, we cannot exclude 
that distinct liposome composition might modulate other membrane features (such as membrane structure) 
that may impact on the stability of membrane-dependent structures, antigen uptake by draining lymph nodes 
and the interaction with antigen presenting cells47. Finally, we have confirmed that addition of the TLR4 agonist 
MPLA, as a molecular adjuvant, considerably enhanced the immunogenicity of the immunogen. Therefore, the 
use of CHOL and SM-containing liposomes in combination with MPLA constitutes an excellent carrier system 
for MPER-based immunogens. The applicability of these carriers to other membrane-dependent antigens will be 
also worth exploring.
A deeper analysis showed that the response of immunized animals was focused on peptide #162, which over-
lapped the HR2 and the MPER regions including the 2F5 binding domain. This peptide is placed at the inter-
face between the lipid-embedded domain of the MPER (C-terminal) and the solvent-exposed HR2 region. The 
immunodominant epitope identified in this peptide included two of the 2F5 neutralizing core residues, the K665 
and W666, the latter one being essential for viral fusion23,24. The immunodominance of this region and the lack 
of response against the C-terminal domain of the MPER may be involved in the modest neutralizing activity 
observed in sera from immunized animals. This observation is surprising since, the C-terminal domain of the 
MPER seems to be properly exposed, as denoted by the similar binding of 4E10 to soluble and proteoliposomal 
preparations of gp41-MinTT protein. In addition, this immunodominance did not depend on the proteoliposome 
composition either, since it was detected regardless of the lipid composition used. Thus, breaking the immuno-
dominance of peptide #162 might be required to extend the response towards the C-terminal moiety of the MPER 
and increase the chance to develop a neutralizing response. Among the different strategies to widen the response, 
the influence of the TM domain should be evaluated. Although the TM domain anchors the MPER to the lipos-
ome avoiding early antigen dissociation69, it may shift the response from the C-terminal to the N-terminal MPER 
helix69. This observation is particularly intriguing in the context of currently available structural data on the 
MPER-TM transition residues. Our model showed that the MPER displayed a mostly alpha-helix conformation, 
as expected from CD data and previously published MPER structures73. However, it shows some level of disorgan-
ization in the MPER-TM joining region due to the tendency of R696 to interact with the polar membrane surface. 
This structure contrasts with previously reported rigid alpha-helix structures of the MPER-TM joining region74. 
Finally, the inclusion of a native-like trimeric transmembrane domain, that may better control for the extent of 
immunogen oligomerization, should also be considered as it might favor better interactions with anti-MPER 
bNAbs75. Therefore, understanding the role of TM in MPER immunogenicity is probably a key issue to develop 
new MPER-based immunogens.
Despite a close specificity by the 2F5 binding motif, sera from immunized animals showed a modest neutraliz-
ing activity. Similarly, an study in rhesus macaques by Dennison et al. showed that antibodies that recognized the 
2F5 neutralizing core epitope (664DKW666), with a preferential binding for the gp41 fusion intermediate, lacked 
neutralizing activity62. Moreover, llama immunized with a gp41 mini protein generated a polyclonal humoral 
response that failed to neutralize HIV-1. However, the later authors isolated a single chain antibody (VHH) that 
binds partially to the 2F5 epitope, but lacked binding to W66655. This antibody became neutralizing when was 
made bivalent and displayed a hydrophobic CDRH3 tip which was essential for neutralization, a common feature 
of many other anti-MPER bNAbs55,56,58. In our case, the low neutralizing activity detected in immunized animals, 
could be also related to the lack of binding to peptide #163 and the observed reactivity against the HR2 region 
of gp41, that may limit the accessibility of antibodies to the target epitope either in the native envelope trimer 
or in the fusion intermediate structures, which are thought to be the main target of MPER bNAbs32,76. Our data 
support the notion that antibodies elicited by proteoliposome immunization extract W666 from the membrane, 
as it has been proposed for other anti-MPER antibodies73; although the response observed here lacked D664 reac-
tivity. Structural information suggests that hydration shells of the different residues may determine the strength 
of charge-charge interactions and therefore the folding structures, the exposure and the reactivity of these key 
residues. However, other factors such as lipid-induced oligomerization may have impacted immunodominance 
of specific residues. Further structural analysis may provide insights for fine tuning of the hydrophobic/solvent 
interactions of these key residues that might impact final neutralization activity.
Overall, the results presented here show that lipid modulation of membrane-dependent antigens impacts 
immunogenicity and elicits potent antibody titers. We propose that CHOL and SM-containing liposomes in 
combination with molecular adjuvants like MPLA constitute excellent vaccine platforms for MPER immunogens. 
Combining these carriers with redesigned immunogens able to modify the exposure and immunogenicity of 
immunodominant residues will help to specifically elicit MPER-neutralizing responses.
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Materials and Methods
Immunogen construction. Protein gp41-Min has been previously described36. A linker of four glycines and 
a TT promiscuous T-helper epitope 830QYIKANSKFIGITEL84438 were added in frame at the end of the transmembrane 
domain of the gp41-Min. The construct was generated by sequential PCR using the gp41-Min plasmid as template 
and the following primers: sense primer: Nco I-MinS 5′ TTTGGCCATGGTTTGGAATAACAT 3′ and the following 
three antisense overlapping primers: Min-TTas1: 5′ GTTCGCTTTAATATACTGGCCACCGCCACCAGCTC-3′ , 
Min-TTas2 5′ ATGCCAATAAATTTGCTGTTCGCTTTAATATACTG-3′ and Min-TTas3 5′ TTTAACTCGAGC 
AGTTCGGTAATGCCAATAAATTTGCTG-3. The final construct was cloned into a pET21d (+ ) plasmid 
(Novagen), in frame with the C-terminal 6xHis tag, using the NcoI and XhoI restriction enzymes (Fermentas).
Recombinant gp41-MinTT production. Gp41-MinTT was produced in E. coli BL21 DE3 strain 
(Invitrogen). Cells were transformed with the plasmid pET-21-d+ Min-TT and cultured in LB medium sup-
plemented with ampicillin. Cells were harvested by centrifugation and lysed with 50 mM Tris-HCl, 100 mM 
NaCl, (pH = 8) buffer supplemented with 2 mg/mL of lysozyme. Crude extract was then treated with 0.5% of 
Triton X-100 and inclusion bodies were collected after centrifugation. Inclusion bodies were solubilized using 
an urea-containing buffer (8 M urea, 20 mM Tris-HCl, 500 mM NaCl, 30 mM imidazole, pH = 8). Gp41-MinTT 
protein was purified by sepharose-Ni2+ affinity chromatography (GE Healthcare). An additional gel filtration 
purification step (Hiprep 16/60 Sephacryl S200 HR, GE Healthcare) was performed in the presence of 1% sodium 
dodecyl sulfate, 20 mM Tris-HCl buffer (pH = 7). Purified gp41-MinTT protein was dialyzed against PBS and 
concentrated with a 3 kDa Amicon Ultra-15 device (Milipore) to reduce SDS concentration to < 0.1%. Purity was 
assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and G-250 coomassie staining (Biorad).
Proteoliposome production and characterization. Large unilamellar vesicles (LUV) were prepared 
following the extrusion method described before77. Briefly, lipids (Avanti Polar Lipids) were mixed in chloro-
form:methanol (2:1) ratio (v/v) and dried under a nitrogen stream. Traces of organic solvent were removed by 
vacuum pumping for 1–2 h. Subsequently, the dried lipid film was dispersed in 50 mM MES, 50 mM Tris, 1 mM 
EDTA (pH 7.3) and subjected to 10 freeze-thaw cycles prior to extruding 10 times through two stacked poly-
carbonate membranes with a 100 nm pore size (Nucleopore) using the Thermo-barrel extruder (Lipex extruder, 
Northern Lipids, Inc.). To make proteoliposome fraction visible, 1% of Rho-DHPE (Molecular Probes) was 
added in the organic phase during LUV preparation. Highly pure Gp41-MinTT and Liposomes were mixed in 
a 1:250 molar ratio, 1:10 (w/w). Octylglucoside (OG) (Sigma-Aldrich) was the detergent used for proteolipos-
ome preparation. OG was removed by extensive dialysis using 14 kDa membranes (Sigma-Aldrich) in 50 mM 
MES, 50 mM Tris, 1 mM EDTA (pH 7.3) buffer, changing the buffer solution every 4–8 hours for two days. The 
sample to buffer ratio used during dialysis was 1:2000 ratio (v/v). Newly formed proteoliposomes were subse-
quently purified by floatation using ultracentrifugation for 210 min through a sucrose gradient (0–25–30% of 
sucrose) in a TLA 120.2 rotor at 100,000 rpm. Each sample was in 30% sucrose. After ultracentrifugation, six 
fractions were collected. The proteoliposomes were layered in the first two fractions as proved by the rhodamine 
fluorescence and the silver staining of each fraction. Once the proteoliposomes were purified, they were imme-
diately freeze-dried in a FreeZone lyophilizer (Labconco). Proteoliposomes were characterized based on their 
vesicle size distribution using a Malvern Zeta-Sizer instrument (Malvern Instruments, Malvern, UK), and their 
lipid/protein quantification. For lipid quantification membrane labeled rhodamine fluorescence was measured 
in a BioTek Synergy HT plate reader. In all cases, Triton X-100 was added to avoid fluorophore quenching effect 
induced by the order degree of different lipid compositions. Protein quantification was achieved by a quantita-
tive Western blot using anti-Histidine (Invitrogen) antibody. Detection was carried out on a LI-COR Odyssey 
system (LI-COR Biosciences) following manufacturer recommendations. All proteoliposomal preparations were 
aliquoted, freeze-dried and stored at − 30 °C, and reconstituted shortly before use.
Secondary Structure Determination. Circular Dichroism (CD) measurements were carried out on a 
thermally-controlled Jasco J-810 circular dichroism spectropolarimeter calibrated routinely with (1S)-(+ )- 
10-camphorsulfonic acid, ammonium salt. The structure of the purified gp41-MinTT protein was measured in 
50 mM Tris, 1 mM EDTA (pH 7.3) buffer at 1 μ M concentration and proteoliposomes were prepared as previ-
ously described using 1:250 protein to lipid molar ratio in POPC (simple) and POPC:SM:CHOL:GM3:PS:MPLA 
(Complex + MPLA) lipid composition. After floatation, only the first fraction was used for CD measurements. 
Buffer or protein-free liposomes signals were subtracted to all spectra. Spectra were recorded between 200–
260 nm in a 0.2 cm path-length quartz cell equilibrated at 20 °C. Data were taken with 1 nm band-width, 20 nm/
min speed, and the results of 5 scans were averaged. The measurements were done with two independent prepa-
rations with similar results.
Experimental Animal modeling and Immunization regimens. Seven-week old female C57 BL/6 
mice were purchased from Harlan Interfauna Iberica (Spain). The animals were shipped under suitable con-
ditions, with the corresponding certificate of health and origin. Upon arrival, mice were kept under controlled 
conditions in a P3 high security facility with sterile food and water “ad libitum”. All animal procedures were per-
formed in accordance with relevant guidelines and regulations and approved by the Animal Care Committee of 
the Germans Trias i Pujol University Hospital and the Department of Environment of the Catalan Government. 
Mice (five per experimental group) were subcutaneously immunized four times at weeks 0, 3, 6 and 9 with proteo-
liposome preparations (2 μ g gp41-MinTT protein: 20 μ g lipids/inoculum), liposomes (20 μ g/inoculum) or recom-
binant gp41-MinTT (20 μ g protein/inoculum), reconstituted in PBS buffer. Mice were examined daily following 
a protocol that monitored weight loss, apparent good health (bristle hair and wounded skin) and behavior (signs 
of aggressiveness or isolation). Blood samples were collected from facial vein before each immunization point 
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as well as at week 10. Mice were euthanized at week 12 with isoflurane (inhalation excess) in order to avoid any 
suffering, and total blood and spleen were collected. Serum was obtained by blood centrifugation at 5000 × g for 
10 minutes.
Peptide and protein antigens. 15-mer overlapping peptides covering the gp41 HR2 and MPER regions were 
obtained from the NIH AIDS Reagent Program (HIV-1 Consensus B Env Peptide Set, cat# 9480). Alanine mutants 
of peptide #162 (QEKNEQELLELDKWA) and a full MPER peptide (EQELLELDKWASLWNWFNITNWLWYIKL) 
were purchased from Covalab. Recombinant gp41-Min protein was produced as described previously36.
Western blot and ELISA assays. For Western blot, samples were loaded onto a NuPAGE® Novex® 
4–12% Bis-Tris Gel (Life Technologies) and blotted using in an iBlot Gel Transfer Device (Life Technologies). 
After blocking (5% w/v skimmed milk PBS buffer + 0.05% v/v Tween 20), membrane was incubated at 4 °C 
overnight with 2F5 (Polymun) antibody. Membrane was then washed in PBS and incubated with Horseradish 
Peroxidase (HRP)-conjugated-F(ab)2 Goat anti-human IgG Fc specific (Jackson Immunoresearch). Membrane 
was developed using an Enhanced Chemioluminiscent HRP substrate (Fisher Scientific). For ELISA, recom-
binant gp41-Min protein and peptides were prepared at 1 μ g/mL and 10 μ g/mL in PBS or carbonate/bicarbo-
nate buffer (pH = 9.6) respectively to coat 96-well Maxisorp Nunc-immuno plates (Fisher Scientific, 50 μ l/well). 
After blocking with 1% bovine serum albumin (Sigma-Aldrich), plates were incubated with 100 ul of previ-
ously diluted serum samples overnight at 4 °C. Plates were then washed and 100 μ l of a (HRP)-conjugated F(ab)2 
Goat anti-mouse IgG (Fc specific, Jackson Immunoresearch) were dispensed for one hour at room temperature. 
Plates were developed with 100 μ l of O-Phenylenediamine dihydrochloride (OPD) substrate (Sigma-Aldrich). 
Optical density was measured at 492 nm for specific signal and at 620 nm for background. A different strategy 
was followed to characterize the antigenicity and orientation of gp41-MinTT within proteoliposomes. Briefly, 
ELISA plates were coated with 50 ng/well of anti-gp41 monoclonal antibody D50 (NIH AIDS Reagent Program, 
cat#11393)78 or 2F5 (Polymun) and, after blocking, complex proteoliposomes (POPC:SM:CHOL) containing 
gp41-MinTT (intact or solubilized by using 0.5% of Tween-20 detergent) or recombinant gp41-MinTT protein 
(30 ng of protein/well in both cases) were added and incubated 2 hours at room temperature. Then, plates were 
incubated sequentially with serial dilutions of 2F5, 4E10 or anti-6xHis (HIS.H8 ThermoFisher, cat# MA1-21315) 
monoclonal antibodies (overnight at 4 °C) and with (HRP)-conjugated F(ab)2 Goat anti-human IgG or F(ab)2 
Goat anti-mouse IgG (Fc specific, Jackson Immunoresearch, 1 hour at room temperature). Plates were developed 
as described above. Proteoliposome ELISA experiments were performed in absence of Tween 20.
Viruses and neutralization assays. Pseudotyped HIV-1 were generated by cotransfection of Env expres-
sion plasmids and the pSG3 vector as described elsewhere79. Virus neutralization by sera samples was tested by a 
standard TZM-bl based assay. Briefly, in a 96-well culture plate, 100ul of previously heat inactivated (56 °C, 30 min-
utes) and 100-fold diluted plasma samples were preincubated with 50 ul of pseudovirus stock (200 TCID50) at 
37 °C for one hour. Then, 100 ul containing 10,000 TZM-bl luciferase-reporter target cells and dextran (10 μ g/mL) 
(Sigma Aldrich) per well were added. Plates were cultured at 37 °C and 5% CO2 for 48 hours. 2F5, 4E10 and 
IgGb12 (Polymun Scientific), and anti-CD4 clone SK3 (BD Biociences) were used as controls. Luciferase substrate 
(Britelite Plus, Perkin-Elmer) was used for the read out.
Structural modeling. Firstly, an in silico structural model of the extracellular and transmembrane segments 
of gp41-Min (including a few residues of the intracellular segment, 707 to 714, to stabilize the transmembrane 
domain) was constructed using Modeller 9v1480. The RCSB Protein Data Bank (PDB) structures 3VGX and 3H01 
were used as templates for HR2 and MPER regions, while 2MG1 structure was used as template for the trans-
membrane domain. Alignment was done using 3D-Coffee81. The best of six models obtained from Modeller, as 
assessed by the DOPE (Discrete Optimized Protein Energy) method, was embedded in a POPC bilayer using 
the VMD82 membrane plugin, solvated with TIP3P water molecules (15 Å as minimal distance to the edge of 
the box). Additionally, Cl− and Na+ ions were added up to a final concentration of 0.15 M. The final structure 
was minimized, thermalized, and then submitted to about 310 ns of molecular dynamics at 310 K, using the 
CHARMM36 force field, with a time step of 2 fs, a cut-off distance for non-bonded interactions of 10 Å and 
Particle-Mesh-Ewald for long-range electrostatic interactions. The same protein structure in the absence of lipids 
was also submitted to a shorter molecular dynamics (150 ns) for comparative analysis. Protein RMSD through-
out the dynamics for the two models is shown in Supplemental Fig. 6. Dynamics were performed with NAMD83 
at BSC supercomputing facilities (Barcelona): Marenostrum (Barcelona) and Finisterrae (Vigo). VMD was 
used for protein dynamics analysis. Secondly, the protein structure previously minimized and thermalized in a 
POPC membrane, was embedded in a bilayer mimicking the lipidic composition of complex proteoliposomes 
(POPC:SM:CHOL) using the CHARMM-GUI Membrane Builder84. Then, the system was truncated (to obtain 
a size similar to the POPC bilayer), solvated and ionized with VMD, and finally submitted to about 150 ns of 
molecular dynamics in the same conditions referred above.
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